Pharmaceuticals
Target Health and dMed Biopharmaceuticals Join Forces to Help Western and Chinese Biopharma and Device Companies
SHANGHAI and NEW YORK, June 24, 2019 /PRNewswire/ -- Target Health Inc. and dMed Biopharmaceuticals Company Limited have joined forces to help Western and Chinese biopharma and device companies capitalize on the rapid internationalization of clinical trials between the US andChina while maintain...
2019-06-25 04:00
2113
Shionogi Concludes Licensing Agreements with Eddingpharm for Lusutrombopag, a Thrombopoietin Receptor Agonist
OSAKA, Japan, June 24, 2019 /PRNewswire/ -- Shionogi & Co., Ltd. (hereafter "Shionogi" or "the Company") announces that the Company has concluded an agreement with Eddingpharm (hereafter "Eddingpharm") to license-out lusutrombopag, a thrombopoietin receptor agonist (brand name inJapan: MULPLETA® ...
2019-06-24 22:00
1875
China Jo-Jo Drugstores Enters into Strategic Cooperation Framework Agreement with Zhejiang Medical Insurance Bureau
HANGZHOU, China, June 24, 2019 /PRNewswire/ -- China Jo-Jo Drugstores, Inc. (NASDAQ: CJJD) ("Jo-Jo Drugstores" or the "Company"), a leading online and offline retailer and wholesale distributor of pharmaceutical and other healthcare products and a healthcare provider inChina, announced today that...
2019-06-24 20:30
7349
CARsgen Therapeutics Receives IND Clearance for BCMA-CAR-T Cells from the U.S. FDA
SHANGHAI, June 19, 2019 /PRNewswire/ -- CARsgen Therapeutics, a clinical-stage company committed to developing Chimeric Antigen Receptor T cell therapies for cancer, today announced that one of its leading drug candidates, CT053 fully human BCMA (B-Cell Maturation Antigen)-CAR-T cell for the trea...
2019-06-19 18:00
4846
Reistone Announces First Patient Dosed in Two Phase II Global Studies of SHR0302 JAK Inhibitor for Ulcerative Colitis and Crohn's Disease
SHANGHAI, June 14, 2019 /PRNewswire/ -- Reistone Biopharma Company Limited (Reistone) announced today dosing of the first patient in their Phase II global clinical trials (RSJ10101 and RSJ10201) of SHR0302 in patients with Ulcerative Colitis and Crohn's disease respectively. The Phase II studies ...
2019-06-14 20:30
2030
New Data Shows The Carillon Mitral Contour System® Is Associated With Improvement In Regurgitant Volume In Patients With Increased Mitral Valve Tenting
Data Presentation & Lunch Symposium at TVT2019 Structural Heart Summit CHICAGO, June 13, 2019 /PRNewswire/ -- Cardiac Dimensions, a leader in the development of minimally invasive treatments for functional mitral regurgitation (FMR) in patients with heart failure, presented data at the TVT2019 S...
2019-06-13 21:10
5789
Lumosa to Initiate Phase 2 Human Clinical Trial in the US and Taiwan for Its LT3001, A Novel Drug for the Treatment of Acute Ischemic Stroke
TAIPEI, , June 13, 2019 /PRNewswire/ -- Lumosa Therapeutics (Lumosa; code: 6535.TWO) announced that the company is ready to commence the Phase 2 proof of concept (PoC) study for its LT3001, a novel drug for the treatment of acute ischemic stroke (AIS) that showed good safety, tolerability and ...
2019-06-13 20:00
4386
CartiHeal Enrolls the 200th Patient in Its Pivotal Clinical Study in San Diego, CA
KFAR SABA, Israel, June 12, 2019 /PRNewswire/ -- CartiHeal, developer of the Agili-C™ implant for treating cartilage and osteochondral defects in traumatic and osteoarthritic joints, successfully enrolled the 200th patient in the Agili-C™ IDE pivotal clinical study. Surgery was performed byScott ...
2019-06-12 20:38
2696
Amcor Completes Acquisition of Bemis, Creating the Global Leader in Consumer Packaging
CHICAGO and MELBOURNE, Australia, June 11, 2019 /PRNewswire/ -- Amcor today announces the successful completion of its acquisition of Bemis Company Inc., effective11 June 2019. The combined company will now operate as Amcor plc (Amcor), trading on the New York Stock Exchange under the ticker symb...
2019-06-11 21:46
3186
Collaborative Medicinal Development, LLC Reports that Lead Drug Shows Dose-Dependent Improvement in Parkinson's Disease
MILL VALLEY, California, June 10, 2019 /PRNewswire/ -- Collaborative Medicinal Development LLC ("CMD"), a privately-held biopharmaceutical company developing innovative therapies for neurodegenerative diseases, will report promising results from its phase 1, non-placebo controlled, dose-finding s...
2019-06-10 20:00
1777
Sihuan's Abstracts regarding Clinical Trial Progress of SGLT-2 Inhibitor Selected for Poster Presentation at the American Diabetes Association's Scientific Sessions
HONG KONG, June 10, 2019 /PRNewswire/ -- Sihuan Pharmaceutical Holdings Group Ltd. (HKEx: 0460), the largest cardio-cerebral vascular drug manufacturer in China's prescription drug market, announced that three abstracts regarding the clinical trial of the Group's patented innovative drug Janaglif...
2019-06-10 16:28
6883
CStone and Bayer announce global collaboration to evaluate PD-L1 monoclonal antibody CS1001 in combination with regorafenib
SUZHOU, China, June 9, 2019 /PRNewswire/ -- CStone Pharmaceuticals ("CStone"; HKEX: 2616) today announced that the company has entered into a global clinical collaboration withChina focus with Bayer HealthCare LLC to evaluate the safety, tolerability, pharmacokinetics (PK) and antitumor activity ...
2019-06-10 09:30
7341
CStone received approval to initiate clinical development in China of CS1001 and BLU-554 (CS3008) in combination therapy for HCC
SUZHOU, China, June 5, 2019 /PRNewswire/ -- CStone Pharmaceuticals (CStone; HKEX: 2616) announced that it has received approval to initiate clinical development inChina of CS1001 in combination with BLU-554 (CS3008) in patients with locally advanced or metastatic hepatocellular carcinoma (HCC). T...
2019-06-05 19:56
7054
Ascentage Pharma presents new clinical data of apoptosis-targeted drug candidates APG-115 and APG-1387 at 2019 ASCO
SUZHOU, China and CHICAGO, June 3, 2019 /PRNewswire/ -- Ascentage Pharma, a globally-focused, clinical-stage biotechnology company engaged in developing novel therapies for cancers, hepatitis B virus and age-related diseases, today announced that the company presented new data of two apoptosis-ta...
2019-06-04 07:00
2416
Aadi Bioscience Breakthrough Therapy nab-Sirolimus (ABI-009) Preliminary Data Released from the AMPECT Registration Trial in Advanced PEComa
Highlights: * 42% investigator-assessed ORR achieved in patients with advanced PEComa – a rare sarcoma with no currently approved therapy * First prospective clinical study in advanced PEComa shows durable responses with nab-sirolimus with a manageable safety profile * 62% of all responding...
2019-06-04 06:39
2496
CStone submits new drug application for TIBSOVO(R) in Taiwan for the treatment of relapsed/refractory AML
HONG KONG, June 2, 2019 /PRNewswire/ -- CStone Pharmaceuticals ("CStone", HKEX: 2616) announced that a new drug application (NDA) for TIBSOVO® (ivosidenib) has been submitted by a third-party to the Taiwan Food and Drug Administration (TFDA) as the first to-be-approved treatment of adult patients...
2019-06-03 11:45
5727
Iovance Biotherapeutics Expands Partnership with WuXi Advanced Therapies Business
PHILADELPHIA, May 31, 2019 /PRNewswire/ -- Iovance Biotherapeutics, a late-stage biotechnology company developing novel cancer immunotherapies based on tumor-infiltrating lymphocyte (TIL) technology, has expanded its relationship with WuXi AppTec's Advanced Therapies Business Unit (WuXi ATU). Wu...
2019-05-31 20:00
2909
Conagen announces formation of Scientific Advisory Board
Board includes five world-leading scientists in the fields of Synthetic Biology and Applied Molecular Biology BEDFORD, Massachusetts, May 30, 2019 /PRNewswire/ -- Conagen Inc., a vertically integrated synthetic biology and fermentation company, announced today the formation of a new scientific ...
2019-05-30 20:00
2151
CartiHeal's Agili-C™ Implant Enhances In-vitro Osteogenic Differentiation of Human Bone Marrow-derived Mesenchymal Stem Cells
KFAR SABA, Israel, May 30, 2019 /PRNewswire/ -- CartiHeal, developer of Agili-C™, a proprietary implant for the treatment of osteochondral and chondral defects, announced today the publication of anin-vitro study demonstrating that the Agili-C™ implant enhances osteogenic differentiation of human...
2019-05-30 20:00
1988
Sihuan Pharm Obtained Phase I to III Clinical Trial Approval for the Third Generation of EGFR Inhibitor XZP-5809
HONG KONG, May 29, 2019 /PRNewswire/ -- Sihuan Pharmaceutical Holdings Group Ltd. (HKEx: 0460), the largest cardio-cerebral vascular ("CCV") drug manufacturer inChina's prescription drug market, announced the third generation of EGFR inhibitor XZP-5809, a Category 1 innovative drug developed by t...
2019-05-29 18:00
4933
Week's Top Stories
Most Reposted
LINKDOOD Breaks Language Barriers, Ushering a New Era for Cross-Border Romance
[Picked up by 326 media titles]
2024-04-29 06:00
Revenue Surpasses 50 Billion: BlueFocus Accelerates Towards the AI Native Era
[Picked up by 276 media titles]
2024-04-23 15:43
INTAMSYS Becomes 3D Printing Equipment Supplier for the WORLDSKILLS LYON 2024 COMPETITION
[Picked up by 274 media titles]
2024-04-24 17:09
Puyuan Fashion Resort 2024: A Grand Unveiling of Global Trends and Local Heritage
[Picked up by 269 media titles]
2024-04-28 09:39
Introducing Wacom Movink: The first OLED pen display, and the thinnest and lightest Wacom pen display ever
[Picked up by 268 media titles]
2024-04-24 13:00
Most Read
Automation Anywhere Appoints Tim McDonough as Chief Marketing Officer to Drive Global Awareness and Growth for the Leader in AI-Powered Automation
2024-04-24 03:57
7859
INTAMSYS Becomes 3D Printing Equipment Supplier for the WORLDSKILLS LYON 2024 COMPETITION
2024-04-24 17:09
6954
Revenue Surpasses 50 Billion: BlueFocus Accelerates Towards the AI Native Era
2024-04-23 15:43
5072